Christophe Beauduin

Special Counsel
Full contact info

Experience

Lexeo Therapeutics Announces $100 Million IPO

November 3, 2023

Cooley advised Lexeo Therapeutics, a clinical-stage gene therapy company advancing gene therapy candidates for genetically defined cardiovascular diseases and a genetically defined subgroup of Alzheimer’s disease, on its approximately $100 million initial public offering.

Read more

Related contacts

Eric Blanchard
Partner, New York
Peter Byrne
Partner, New York
Div Gupta
Partner, New York
Ivor Elrifi
Partner, New York
Matthew Pavao
Partner, Boston
Xander Lee
Partner, Los Angeles Santa Monica
Barbara Mirza
Partner, Los Angeles Santa Monica
Aaron Pomeroy
Partner, Colorado
Phil Mitchell
Partner, New York
Mark Ballantyne
Partner, Reston
Francis Wheeler
Partner, Colorado
Natasha Leskovsek
Of Counsel, Washington, DC
Stephanie Parker Palmer
Special Counsel, Reston
Joseph Lockinger
Special Counsel, Washington, DC
Christophe Beauduin
Special Counsel, New York
Randy Sabett
Special Counsel, Washington, DC
Jennifer Shanley
Special Counsel, New York
Reid Hooper
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC
Dayne Brown
Associate, New York
Ibe Alozie
Associate, Washington, DC
Christopher Nickas
Associate, New York
DeVon Barnett
Associate, Washington, DC
Carly Robinson
Associate, Reston
Calvin Lee
Associate, New York
Jayne M. Munger
Associate, New York
Megan Drill
Associate, San Diego
Erika Freeman
Associate, New York
Mor Agam
Associate, New York
Wyatt Kernell
Associate, New York
Wyatt Kernell
Associate, New York
Alexander Fullman
Associate, New York
Jason Minio
Paralegal Specialist, Boston
Andrew Henderson
Patent Agent, Seattle

Related Practices & Industries

Beam Announces Agreement for Lilly to Acquire Opt-In Rights to Verve Therapeutics’ Base-Editing Programs for Cardiovascular Disease

October 31, 2023

Cooley advised Beam Therapeutics, a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines, on its agreement with Verve Therapeutics to sell its opt-in rights to co-develop and co-commercialize base-editing programs for cardiovascular disease to Eli Lilly and Company.

Read more

Related contacts

Kenneth Krisko
Partner, Reston
Christophe Beauduin
Special Counsel, New York
Jiqiang Lin
Associate, New York
Jameson Davis
Associate, Palo Alto
Eric Blanchard
Partner, New York
Wouter Deleersnyder
Associate, New York
Jayne M. Munger
Associate, New York
Michael Tollini
Partner, Washington, DC
Matthew S. Scarano
Associate, San Diego
Matt Kong
Associate, San Francisco
Eileen Marshall
Partner, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
Rachel Thorn
Partner, New York
Sharon Connaughton
Special Counsel, Washington, DC
Jacqueline Grise
Partner, Washington, DC
Marty Schenker
Senior Counsel , San Francisco
Michael McMahon
Partner, Boston

Related Practices & Industries

Scorpion Therapeutics Announces Collaboration and License Agreement With Pierre Fabre to Co-Develop and Commercialize STX-721 and STX-241

April 4, 2023

Boston – April 4, 2023 Cooley advised Scorpion Therapeutics on its exclusive license agreement with Pierre Fabre to co-develop and commercialize STX-721 and STX-241. Lawyers Christophe Beauduin, Carly Robinson, Michael Klein, Evan Lazerowitz and Aaron Pomeroy led the Cooley team.

The exclusive collaboration and license agreement granted Pierre Fabre a royalty-bearing license to develop and commercialize STX-721 and STX-241, two next-generation mutant epidermal growth factor receptor (EGFR) inhibitors for patients with EGFR-mutant non-small cell lung cancer. Scorpion will lead clinical development of STX-721, and Pierre Fabre will lead clinical development of STX-241. Scorpion will retain commercialization rights to STX-721 and STX-241 in the US, Canada and Japan, while Pierre Fabre will be responsible for commercialization activities in all other territories – with a focus on Europe and China.

Under the terms of the agreement, Scorpion will receive a combined $65 million from an upfront payment and achievement of near-term milestones – and will be eligible to receive up to a total of $553 million in potential milestone payments. In addition, Pierre Fabre will pay Scorpion tiered percentage royalties on a licensed product-by-licensed product basis, ranging from mid-single to mid-teens based on annual net sales of each licensed product in territories excluding the US, Canada and Japan. Scorpion will pay Pierre Fabre tiered percentage royalties based on a licensed product-by-licensed product basis, ranging from low-single to low-double digits on annual net sales of each licensed product in the US. The companies will share global development expenses based on a pre-specified cost-sharing arrangement.

Read more

Related contacts

Christophe Beauduin
Special Counsel, New York
Carly Robinson
Associate, Reston
Michael Klein
Partner, New York
Evan Lazerowitz
Associate, New York
Aaron Pomeroy
Partner, Colorado

CinCor Pharma to Sell to AstraZeneca for Approximately $1.8 Billion

January 10, 2023

Cooley advised CinCor Pharma, a clinical-stage biopharmaceutical company, on its definitive agreement to be acquired by AstraZeneca. M&A partners Rama Padmanabhan and Rowook Park and corporate partners Div Gupta and Sarah Sellers led the Cooley team.

Read more

Related contacts

Rowook Park
Partner, San Diego
Rama Padmanabhan
Partner, San Diego
Div Gupta
Partner, New York
Sarah Sellers
Partner, New York
Christophe Beauduin
Special Counsel, New York
Izzy Lubarsky
Partner, New York
Alessandra Murata
Partner, Palo Alto
Ajay Athavale
Associate, San Francisco
Megan Drill
Associate, San Diego
Melissa Meza
Associate, San Diego
Trey Reilly
Associate, New York
Amy Hallman Rice
Special Counsel, San Diego
Matthew D. Silverman
Special Counsel, San Diego
Howard Morse
Partner, Washington, DC
Sharon Connaughton
Special Counsel, Washington, DC
Rubin Waranch
Associate, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
Phil Mitchell
Partner, New York
Charity Williams
Partner, San Diego
MaryBeth Shreiner
Special Counsel, Reston
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Patrick Sharma
Associate, Los Angeles Santa Monica
Karen Tsai
Special Counsel, Washington, DC
Heidi A. Erlacher
Partner, Boston
Kristopher Kleiner
Special Counsel, Colorado
Ryan Sansom
Partner, Boston
Stephanie Gentile
Partner, New York
Aric Wu
Partner, New York
Christopher Kimball
Partner, Washington, DC
Nyron J. Persaud
Partner, New York
Helenanne Connolly
Partner, Reston
Stella Sarma
Special Counsel, Brussels
Stella Sarma
Special Counsel, Brussels
Stacey A. Bradford
Special Counsel, Washington, DC
Christine Graham
Special Counsel, London
Dillon Martinson
Special Counsel, Washington, DC
Lindsey O'Crump
Associate, Washington, DC
Arman Sagart
Associate, San Diego
Daniel Gillon
Associate, San Diego
Barry Kuang
Associate, Boston
Rajdeep Roger Bains
Associate, San Diego
Alexander Fullman
Associate, New York
Amanda Gonzalez Burton
Associate, New York
Grace Hunter
Associate, Washington, DC
Kindall G. Jackson
Associate, Washington, DC
Dr. Xixi Sun
Associate, Boston
Sarah Curry
Associate, New York
Carly Mitchell
Partner, Washington, DC
Jennifer Shanley
Special Counsel, New York
Wyatt Kernell
Associate, New York
Allison Kutner
Associate, New York

Related Practices & Industries

Scorpion Therapeutics Enters Collaboration Agreement with AstraZeneca

January 14, 2022

Cooley advised Scorpion Therapeutics in its collaboration agreement with AstraZeneca to discover, develop and commercialize precision medicines against previously hard-to-target cancer proteins, with the potential to transform oncology treatment.

Under the terms of the collaboration agreement, Scorpion will receive an upfront cash payment of $75 million and is eligible to receive additional success-based payments in the form of option fees and milestone payments, as well as tiered royalties on net sales ranging from mid-single digit to low-double digits. In the event Scorpion opts into co-developing and co-promoting a nominated program, Scorpion will participate in the operating costs and be entitled to a proportionate share of the economics in the US, subject to certain adjustments.

 

Related contacts

Christophe Beauduin
Special Counsel, New York
Carly Robinson
Associate, Reston

Related Practices & Industries

View more